Pharma Report on Uveal Melanoma – Pipeline Review, H2 2020


Uveal Melanoma – Pipeline Review, H2 2020


Uveal Melanoma – Pipeline Review, H2 2020, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Uveal Melanoma – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 17, 10, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Phase I stages comprises 1, 2 and 2 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
A6 Pharmaceuticals LLC
AbbVie Inc
Aeglea BioTherapeutics Inc
Astex Pharmaceuticals Inc
Aura Biosciences Inc
Bellicum Pharmaceuticals Inc
Biocon Ltd
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Cleveland BioLabs Inc
Delcath Systems Inc
Dompe Farmaceutici SpA
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
GlaxoSmithKline Plc
Ideaya Biosciences Inc
Immunocore Ltd
InxMed Shanghai Co Ltd
iOnctura SA
Iovance Biotherapeutics Inc
Modulation Therapeutics Inc
Novartis AG
Okogen Inc
Oncomatryx Biopharma SL
OncoSpherix Inc
PEP-Therapy SAS
Pfizer Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Verastem Inc
Viralytics Pty Ltd
WPD Pharmaceuticals Inc

For queries regarding this report:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.